Access to new cancer medicines in Australia: dispelling the myths and informing a public debate-Reference-Cited by-同舟云学术

Access to new cancer medicines in Australia: dispelling the myths and informing a public debate

Published:2016-04-07 Issue:1 Volume:9 Page:
ISSN:2052-3211
Container-title:Journal of Pharmaceutical Policy and Practice
language:en
Short-container-title:J of Pharm Policy and Pract

Author:

Vitry Agnes,Mintzes Barbara,Lipworth Wendy

Publisher

Springer Science and Business Media LLC

Subject

Pharmacy,Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s40545-016-0062-x

Reference51 articles.

1. Medicines Australia. Oncology Industry Taskforce 2013. http://medicinesaustralia.com.au/issues-information/oncology-industry-taskforce/ . Accessed 23 Dec 2015.

2. Cancer Drugs Alliance. 2013. http://www.cancerdrugsalliance.org.au/ . Accessed 23 Dec 2015.

3. Australian Institute of Health and Welfare, Australian Association of Cancer Registries. Cancer in Australia: an overview, 2012. Cancer series. Canberra: AIHW; 2012.

4. Currow D, Aranda S. Cancer control is not beyond us…but could be if we dont invest wisely. MJA. 2015;202(2):63–4.

5. Australian Government, Department of Health. Pharmaceutical Benefits Scheme. 2015. http://www.pbs.gov.au/pbs/home . Accessed 13 Dec 2015.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice;World Journal of Oncology;2024-06

2. Reimbursement of interventional oncology in Australia: How it works and how it does not;Journal of Medical Imaging and Radiation Oncology;2023-12

3. Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease;PharmacoEconomics - Open;2023-06-12

4. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries;BMC Health Services Research;2022-08-20

5. Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland;Irish Journal of Medical Science (1971 -);2022-04-21